


# **MEMORIAL SLOAN KETTERING CANCER CENTER CURRICULUM VITAE FORM**

**(REQUIRED FORMAT)**

Signature (required):	
Version date:	11/09/2020

## **A. GENERAL INFORMATION**

### **Required Information:**

Name: First, Middle, Last	Lindsey Elizabeth Roeker
Office address:	530 E 74th St, New York, NY 10021
Office telephone:	262-391-5431
Office fax:	N/A
Home address:	435 E 70 <sup>th</sup> St, Apt 19J, New York, NY 10021
Home telephone:	262-391-5431
Cell phone:	262-391-5431
Beeper:	3897
Work Email:	<a href="mailto:roekerl@mskcc.org">roekerl@mskcc.org</a>
Personal Email:	<a href="mailto:lroeker@gmail.com">lroeker@gmail.com</a>
Citizenship:	USA
If not a U.S. Citizen, do you have:	N/A

## **B. EDUCATIONAL BACKGROUND**

### 1. Academic Degree(s):

Degree (abbreviation)	Institution Name and Location	Dates attended (mm/yy-mm/yy)	Year Awarded
B.S.	<b>Georgetown University</b> Washington, DC, USA	08/06 – 05/10	2010
M.D.	<b>Mayo Clinic Alix School of Medicine</b> Rochester, MN, USA	07/10 – 05/14	2014

2. Post-doctoral training (include residency/fellowships):

Title	Institution name and location	Dates held (mm/yy-mm/yy)
Internal Medicine Internship & Residency	<b>Brigham and Women's Hospital</b> Boston, MA, USA	07/14 – 06/17
Hematology/Oncology Fellowship	<b>Memorial Sloan Kettering Cancer Center</b> New York, NY, USA	07/17 – 06/20

3. Continuing Medical Education Courses/Certificates

Certificate or Course	Institution Name and Location	Dates attended (mm/yy-mm/yy)
Clinical Research Methodology Curriculum Certificate Program	<b>Clinical and Translational Science Center at Weill Cornell Medical Center</b> New York, NY, USA	09/18 – 07/19

4. Other Educational Experiences

Description	Institution Name and Location	Dates attended (mm/yy-mm/yy)

**C. LICENSURE, BOARD CERTIFICATION, MALPRACTICE**

1. Licensure:

a. State	Number	Date of issue	Date of last registration
Massachusetts	268806	9/8/2016	9/8/2016
New York	287693	2/2/2017	2/28/2020
New Jersey	25MA10859600	6/12/2020	6/12/2020

b. If no license:	
1. Do you have a temporary certificate?	NA
2. Have you passed the examination for foreign medical school graduates?	NA

c. DEA number:	FR6521353
d. NPI number:	1497168538

2. Board Certification

Full Name of Board	Certificate #	Dates of Certification (mm/dd/yyyy) – Start and End Dates

American Board of Internal Medicine	379819	08/22/2017 – 12/31/2027
-------------------------------------	--------	-------------------------

3. Malpractice Insurance

Do you have Malpractice Insurance?	Yes
Name of Provider: MSK Insurance, US	
Premiums paid by (choose one):	
Institution (name): Memorial Sloan Kettering Cancer Center	

**D. PROFESSIONAL POSITIONS AND EMPLOYMENT**

1. Academic positions (teaching and research)

Title	Institution name and location	Dates held (mm/yy-mm/yy)
Assistant Member (Level 1)	<b>Memorial Sloan Kettering Cancer Center</b> New York, NY	07/20 - present
Instructor in Medicine	<b>Weill Cornell Medical College</b> New York, NY	08/20 - present

2. Hospital positions (e.g., attending physician)

Title	Institution name and location	Dates held (mm/yy-mm/yy)
Chief Resident	<b>Brigham and Women's Faulkner Hospital</b> Boston, MA	01/17 – 03/17
Chief Medical Oncology Fellow	<b>Memorial Sloan Kettering Cancer Center</b> New York, NY	07/18 – 07/19
Assistant Attending Physician	<b>Memorial Hospital for Cancer and Allied Diseases</b> New York, NY	07/20 - Present

3. Other Employment

Title	Institution name and location	Dates held (mm/yy-mm/yy)
N/A		

**E. EMPLOYMENT STATUS (current or anticipated)**

Name of Employer(s): Memorial Sloan Kettering Cancer Center
---

Full-time salaried by Cornell-affiliated hospital

**F. INSTITUTIONAL/HOSPITAL AFFILIATION**

1. Primary Hospital Affiliation:	Memorial Hospital for Cancer and Allied Diseases
2. Other Hospital Affiliations:	
3. Other Institutional Affiliations:	Weill Cornell Medical College

**G. PERCENT EFFORT AND INSTITUTIONAL RESPONSIBILITIES**

Current % EFFORT	(%)	Does the activity involve WCMC students/researchers? (Yes/No)	Does the activity involve MSK students/researchers? (Yes/No)
TEACHING			
CLINICAL	40	Yes	Yes
ADMINISTRATIVE			
RESEARCH	60	No	Yes
TOTAL	100		

**INSTITUTIONAL RESPONSIBILITIES**

1. Teaching (e.g., specific teaching functions, courses taught, dates:

<b><u>Didactic teaching:</u></b>	
<b>Mayo Clinic Alix School of Medicine: Step 1 preparatory course</b> Developed and instructed lectures on epidemiology, biostatistics, microbiology, and cardiology for second year medical students.	11/2012 – 04/2013
<b>Mayo Clinic Alix School of Medicine: Hematology course</b> Served as a preceptor for discussion sessions for second year medical students taking hematology physiology and pathology course.	03/2013 – 10/2013
<b>Brigham and Women’s Hospital Internal Medicine Residency: Intern curriculum</b> Developed case-based and simulation center sessions for first year resident education on topics including empiric antibiotics, acid-base interpretation, electrolyte management, chest pain, and hypoxia.	06/2015 – 08/2016
<b>Brigham and Women’s Hospital Internal Medicine Residency: Clinical pathologic conference committee</b> Developed case reports for monthly clinical pathologic conferences presented to internal medicine residents and faculty.	06/2016 – 06/2017
<b>Brigham and Women’s Hospital Internal Medicine Residency: Oncology curriculum development</b> Developed myeloma curriculum materials distributed to all internal medicine residents for team-based learning.	08/2015 – 12/2015
<b>Brigham and Women’s Hospital Internal Medicine Residency: Faulkner Hospital chief medical resident</b>	01/2017 – 03/2017

Prepared and presented daily morning report and teaching conference, weekly department of medicine grand rounds for rotating medicine residents.	
<b><u>Mentorship:</u></b>	
N/A	Dates
<b><u>Clinical teaching:</u></b>	
N/A	Dates
<b><u>Administrative teaching leadership role:</u></b>	
N/A	Dates

2. Clinical care (duties, dates):

	Dates
8 weeks inpatient attending per year; 1.5 days outpatient clinic per week	07/20 - Present

3. Research (duties, dates):

Research Activity / Key Contributions	Dates
<p><b>Georgetown University, Chemistry Department</b>  <b><i>Effects of siloxane monolayers on protein crystal growth</i></b>  I performed basic science experiments as a member of the Dr. Jennifer Swift's laboratory in the Chemistry Department. Through these experiments, I aimed to determine if nucleation and growth of protein crystals on siloxane monolayer templates conveyed advantages relative to conventional methods. I was awarded a research fellowship through the Arnold and Mabel Beckman Foundation in support of this work.</p> <ul style="list-style-type: none"> <li>• <b>Roeker LE</b>, Goldberg I, Swift JA. Lysozyme crystallization on siloxane monolayers. Poster session presented at: American Crystallographic Association Annual Meeting; 2009 Jul 25-30; Toronto, Canada.</li> <li>• <b>Roeker LE</b>, Goldberg I, Swift JA. Lysozyme crystallization on siloxane monolayers. Poster session presented at: 238th American Chemical Society National Meeting; 2009 Aug 16-20; Washington, DC.</li> </ul>	04/2009 – 05/2010
<p><b>Mayo Clinic, Family Medicine Department</b>  <b><i>Cervical cancer screening in urban and semi-rural communities in Ghana, assessment of the understanding of reproductive health in Ghana</i></b>  I worked with a team of medical students in collaboration with family medicine faculty at Mayo Clinic, and Gynecology and Pathology faculty at Komfo Anokye Teaching Hospital to develop this research and service project. We studied the prevalence of cervical cancer in rural Ghana and further characterized women's understanding of reproductive health and disease prevention in these communities. We were awarded a Family Medicine research grant, designed the study, provided clinical care in association with the project, analysed data, and prepared data for presentation.</p> <ul style="list-style-type: none"> <li>• Handlogten KS*, Molitor RJ*, <b>Roeker LE*</b>, Narla NP*, Bachman MJ*, Quayson S, Owusu-Afriyie O, Adjei E, Ankobea F, Clayton A, Roberts L, MacLaughlin K, Ansong D. Cervical cancer screening in urban and semi-rural communities in Ghana and</li> </ul>	05/2012 – 06/2011

<p>assessing the understanding of reproductive health in Ghana. Poster session presented at: Mayo Clinic Family Medicine Forum; 2011 Nov; Rochester, MN. (*co-first authorship)</p> <ul style="list-style-type: none"> <li>• Handlogten KS*, Molitor RJ*, <b>Roeker LE*</b>, Narla NP*, Bachman MJ*, Quayson S, Owusu-Afriyie O, Adjei E, Ankobea F, Clayton A, Roberts L, MacLaughlin K, Ansong D. Assessing the understanding of reproductive health in Ghana, West Africa. Poster session presented at: Minnesota Academy of Family Physicians Innovation and Research Forum; 2012 Mar; Bloomington, MN. (*co-first authorship)</li> <li>• Handlogten KS*, Molitor RJ*, <b>Roeker LE*</b>, Narla NP*, Bachman MJ*, Quayson S, Owusu-Afriyie O, Adjei E, Ankobea F, Clayton A, Roberts L, MacLaughlin K, Ansong D. Cervical cancer screening in Ghana, West Africa: Prevalence of abnormal cytology and challenges for expanding screening. <i>Int J Gynecol Pathol</i> 2014 Mar;33(2):197-202. (*co-first authorship)</li> </ul>	
<p><b>Mayo Clinic, Hematology Department</b>  <b>Clinical outcomes of patients with treatment-related acute myeloid leukemia (t-AML)</b>  Under the mentorship of Dr. Aref Al-Kali, I described treatment course, clinical and biologic characteristics, and outcomes for patients diagnosed with t-AML. I designed the study, collected and analysed data, and prepared data for presentation. I was awarded the ASH abstract achievement award at the ASH national meeting for this work.</p> <ul style="list-style-type: none"> <li>• <b>Roeker LE</b>, Wolanskyj A, Elliott M, Hogan W, Litzow M, Al-Kali A. Treatment-related AML patients previously treated with taxanes for breast cancer have similar outcomes as de novo AML. <i>Blood</i> 2012;120:3555. (ASH Abstract Achievement Award Winner)</li> <li>• Fossum CC, Ketterling RP, <b>Roeker LE</b>, Dias AL, Elliot MA, Hogan WJ, Litzow MR, Al-Kali A. Clinical outcome of therapy-related acute myeloid leukemia is strongly related to cytogenetic analysis. <i>Blood</i> 2015;126:1401.</li> </ul> <p><b>Plasma cell leukemia definition and prognosis</b>  This clinical research project under the mentorship of Dr. Vincent Rajkumar compared patients diagnosed with plasma cell leukemia (PCL) to those with multiple myeloma to assess the clinical appropriateness of the definition of PCL. I was involved in study design and primarily responsible for data collection and analysis. I was awarded the Alpha Omega Alpha Carolyn L. Kuckein Student Research Fellowship to support this research, which resulted in a manuscript suggesting revision of the diagnostic criteria for PCL.</p> <ul style="list-style-type: none"> <li>• Ravi P, Kumar SK, <b>Roeker L</b>, Gonsalves W, Buadi F, Lacy MQ, Go RS, Dispenzieri A, Kapoor P, Lust JA, Dingli D, Lin Y, Russell SJ, Leung N, Gertz MA, Kyle RA, Bergsagel PL, Rajkumar SV. Revised diagnostic criteria for plasma cell leukemia: Results of a Mayo Clinic study with comparison of outcomes to multiple myeloma. <i>Blood Cancer J</i> 2018 Nov 15;8(12):116.</li> </ul> <p><b>Cancer development in patients with monoclonal gammopathies</b>  This clinical research project under the mentorship of Dr. Vincent Rajkumar aimed to understand risk of solid and hematologic malignancy development in patients with monoclonal gammopathies. Along with my mentor, I designed these projects, collected data, performed data analysis, and prepared findings for publication. This project resulted in an oral presentation at the ASH annual meeting, as well as a first author publication in <i>Leukemia</i>.</p> <ul style="list-style-type: none"> <li>• <b>Roeker LE</b>, Larson D, Kyle RA, Kumar S, Dispenzieri A, Rajkumar SV. Development of myelodysplastic syndrome and acute leukemias in patients with monoclonal gammopathy of undetermined significance (MGUS): A population-based study of 17,315 patients. <i>Blood</i> 2012;120:21.</li> <li>• <b>Roeker LE</b>, Larson DR, Kyle RA, Kumar S, Dispenzieri A, Rajkumar SV. Risk of acute leukemia and myelodysplastic syndromes in patients with monoclonal gammopathy of undetermined significance (MGUS): A population-based study of 17 315 patients. <i>Leukemia</i> 2013 Jun;27(6):1391-3.</li> </ul>	<p>06/2011 – 05/2014</p>

<ul style="list-style-type: none"> <li>• <b>Roeker LE</b>, Larson D, Kyle R, Kumar SK, Dispenzieri A, Rajkumar V. Development of solid malignancies in patients with monoclonal gammopathy of undetermined significance (MGUS): A population-based study of 17,315 patients. <i>Blood</i> 2013;122:3134.</li> </ul> <p><b>Solid organ transplantation for amyloidosis</b></p> <p>These projects were performed in collaboration with faculty from hematology, cardiology, and hepatology to describe outcomes for patients who underwent solid organ transplantation for AL or TTR amyloid. I was involved in data collection and preparation of data for presentation.</p> <ul style="list-style-type: none"> <li>• <b>Roeker LE</b>, McCurdy AR, Grogan M, Dispenzieri A, Gertz M, Kushwaha S, Lacy MQ, Edwards B. Cardiac transplantation in immunoglobulin light chain amyloidosis: A large single center experience. <i>J Am Coll Cardiol</i> 2014;63(12):A887.</li> <li>• Banerjee D, <b>Roeker LE</b>, Poterucha JJ, Heimbach J, Grogan M, Dispenzieri A. Outcomes of patients with familial transthyretin amyloidosis after liver transplantation. <i>Hepatology</i> 2015;62(S1):1263.</li> <li>• Grogan M, Gertz M, McCurdy A, <b>Roeker L</b>, Kyle R, Kushwaha S, Daly R, Dearani J, Rodeheffer R, Frantz R, Lacy M, Hayman S, McGregor C, Edwards B, Dispenzieri A. Long term outcomes of cardiac transplant for immunoglobulin light chain amyloidosis: The Mayo Clinic experience. <i>World J Transplant</i> 2016 Jun 24;6(2):380-8.</li> <li>• Banerjee D, <b>Roeker LE</b>, Grogan M, Swiecicki P, Poterucha J, Heimbach J, Zeldenrust S, Gertz M, Edwards B, Daly R, Klarich KW, Dispenzieri A. Outcomes of patients with familial transthyretin amyloidosis after liver transplantation. <i>Prog Transplant</i> 2017 Sep;27(3):246-250.</li> </ul>	
<p><b>Dana Farber Cancer Institute, Bone Marrow Transplant Service</b></p> <p><b>Clinical predictors of VOD development</b></p> <p>Under the mentorship of Drs. Robert Soiffer and Vincent Ho, this clinical research project examined stem cell transplant outcomes, specifically clinical predictors of veno-occlusive disease development in allogeneic stem cell transplant patients. I was involved in study design and responsible for data collection, analysis, and presentation. This project resulted in an oral presentation at the American Society for Blood and Marrow Transplantation annual meeting and a first author publication. Based on my experience from this project, I also authored a book chapter on veno-occlusive disease for the “Handbook of Stem Cell Transplantation and Cellular Therapies,” Springer Publishing.</p> <ul style="list-style-type: none"> <li>• <b>Roeker LE</b>, Kim HT, Ho VT, Richardson PG, Soiffer RJ. Early clinical predictors of hepatic veno-occlusive disease after myeloablative hematopoietic stem cell transplantation: A single-center report of 205 cases. <i>Biol Blood Marrow Transplant</i> 2017;23(3):S94.</li> <li>• <b>Roeker LE</b>, Kim HT, Glotzbecker B, Nageshwar P, Nikiforow S, Koreth J, Armand P, Cutler C, Alyea EP, Antin JH, Richardson PG, Soiffer RJ, Ho VT. Early clinical predictors of hepatic veno-occlusive disease/sinusoidal obstruction syndrome after myeloablative stem cell transplantation. <i>Biol Blood Marrow Transplant</i> 2019 Jan;25(1):137-144.</li> <li>• Lewis C, Kim HT, <b>Roeker LE</b>, Cutler C, Koreth J, Nikiforow S, Armand P, Gootpu M, Romee R, Glotzbecker B, Nageshwar P, Antin JH, Alyea EP, Richardson P, Soiffer RJ, Ho VT. Incidence, predictors, and outcomes of veno-occlusive disease/sinusoidal obstruction syndrome after reduced-intensity allogeneic hematopoietic cell transplantation. <i>Biol Blood Marrow Transplant</i> 2020 Mar;26(3):529-539.</li> </ul>	07/2015 – 06/2017
<p><b>Memorial Sloan Kettering Cancer Center, Leukemia Service CLL Program</b></p> <p>I have been heavily involved in clinical research focused on chronic lymphocytic leukemia (CLL) under the mentorship of Dr. Anthony Mato. My research efforts have focused on development and execution of clinical trials, correlative projects, and large, multicenter</p>	03/2018 - Present

retrospective cohort studies. I currently serve as principle investigator for a phase I trial and co-PI for several trials for CLL and Richter's transformation patients. I am additionally developing several IST concepts with integrated translational projects in various phases of development. Regarding development of correlative studies, I was awarded an ASH Research Training Award for Fellows for examination of intestinal microbiota and response to an immunotherapy-based regimen in CLL and RT under the mentorship of Drs. Marcel van den Brink and Jonathan Peled. I have additionally worked with Drs. Omar Abdel-Wahab, Justin Taylor, and Phil Wong to develop correlative studies examining pharmacodynamics and changes in T cell repertoire. Finally, through the CLL Outcomes Consortium, a large network of national and international centers, I have created large datasets designed to answer questions for which prospective data are not available.

- Mato AR\*, **Roeker LE\***, Allan JN, Pagel JM, Brander DM, Hill BT, Cheson BD, Furman RR, Lamanna N, Tam CS, Handunnetti S, Jacobs R, Lansigan F, Bhavsar E, Barr PM, Shadman M, Skarbnik AP, Goy A, Beach DF, Svoboda J, Pu JJ, Sehgal AR, Zent CS, Tuncer HH, Schuster SJ, Pickens PV, Shah NN, Rhodes J, Ujjani CS, Nabhan C. Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial. *Am J Hematol* 2018 Nov;93(11):1394-1401. (\*co-first authorship)
- Mato AR\*, **Roeker LE\***, Eyre TA, Nabhan C, Lamanna N, Hill BT, Brander DM, Barr PM, Lansigan F, Cheson BD, Singavi AK, Sarraf Yazdy M, Shah NN, Allan JN, Bhavsar EB, Rhodes J, Kennard K, Schuster SJ, Williams AM, Skarbnik AP, Goy AH, Goodfriend JM, Dorsey C, Coombs CC, Tuncer H, Ujjani CS, Jacobs R, Winter AM, Pagel JM, Bailey N, Schuh A, Shadman M, Sitlinger A, Weissbrot H, Muralikrishnan S, Zelenetz A, Kirkwood AA, Fox CP. A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL. *Blood Adv* 2019 May 28;3(10):1568-1573. (\*co-first authorship)
- **Roeker LE**, Fox CP, Eyre TA, Brander D, Allan JN, Schuster SJ, Nabhan C, Hill BT, Shah NN, Lansigan F, Sarraf Yazdy M, Cheson BD, Lamanna N, Singavi AK, Coombs CC, Barr PM, Skarbnik AP, Shadman M, Ujjani CS, Tuncer HH, Winter AM, Rhodes J, Dorsey C, Morse H, Kabel C, Pagel JM, Williams AM, Jacobs R, Goy A, Muralikrishnan S, Pearson LK, Sitlinger A, Bailey N, Schuh A, Kirkwood AA, Mato AR. Tumor lysis, adverse events, and dose adjustments in 297 venetoclax treated CLL in routine clinical practice. *Clin Cancer Res* 2019 Jul 15;25(14):4264-4270.
- **Roeker LE**, Sarraf Yazdy M, Rhodes J, Goodfriend J, Narkhede M, Carver J, Mato A. Hypertension in patients treated with ibrutinib for chronic lymphocytic leukemia (CLL). *JAMA Network Open* 2019 Dec 2;2(12):e1916326.
- Mato AR\*, **Roeker LE\***, Jacobs R, Hill BT, Lamanna N, Brander D, Shadman M, Ujjani CS, Sarraf Yazdy M, Perini GF, Pinilla-Ibarz JA, Barrientos J, Skarbnik AP, Torka P, Pu JJ, Pagel JM, Gohil S, Fakhri B, Choi M, Coombs CC, Rhodes J, Barr PM, Portell CA, Parry H, Garcia CA, Whitaker KJ, Winter AM, Sitlinger A, Khajavian S, Grajales-Cruz AF, Isaac KM, Shah P, Akhtar OS, Pocock R, Lam K, Voorhees TJ, Schuster SJ, Rodgers TD, Fox CP, Martinez-Calle N, Munir T, Bhavsar EB, Bailey N, Lee JC, Weissbrot HB, Nabhan C, Goodfriend JM, King AC, Zelenetz AD, Dorsey C, Bigelow K, Cheson BD, Allan JN, Eyre TA. Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK inhibition as an Effective Strategy. *Clin Cancer Res* 2020 Jul 15;26(14):3589-3596.

4. Administrative Activities (duties, dates):

Administrative Activity	Date
MSKCC Graduate Medical Education Committee Member, Learning Environment Subcommittee Member	07/2018 – 06/2019



MSKCC Operational Excellence 101, Critical Values Reporting Committee Member	04/2019 – 03/2020
MSKCC Grand Rounds Planning Committee Member	10/2020 - Present

## H. RESEARCH SUPPORT

Summarize Past Research Support:

<p>1. Arnold and Mabel Beckman Foundation Beckman Scholar \$20,000, 03/2009 – 06/2010 Principle investigator: Jennifer Swift; Awarded Investigator: Lindsey Roeker I performed basic science experiments to examine the effects of siloxane monolayers on protein crystal growth.</p>
<p>2. Mayo Clinic Family Medicine Research Grant \$15,000, 06/2011 Co-Principle Investigator, Awarded Investigator: Lindsey Roeker This funded research and service project aimed to study the prevalence of cervical cancer in rural Ghana and further characterize women’s understanding of reproductive health and disease prevention in these communities.</p>
<p>3. Alpha Omega Alpha Carolyn L. Kuckein Student Research Fellowship \$6,000, 04/2013 – 04/2014 Principle Investigator: Vincent Rajkumar; Awarded Investigator: Lindsey Roeker I aimed to compare patients diagnosed with plasma cell leukemia to those with multiple myeloma to assess the clinical appropriateness of the definition of plasma cell leukemia.</p>
<p>4. MSK Clinical Scholars Award, Internal Funding 100% Salary Support, 07/2018 – 06/2019 Awarded Investigator: Lindsey Roeker I was granted this award on the basis of a clinical trial examining the safety of ibrutinib discontinuation in patients who achieve deep responses with ibrutinib monotherapy. I was responsible for LOI development, protocol development and writing, and implementation of the clinical trial.</p>
<p>5. Memorial Sloan Kettering Cancer Center Mortimer J. Lacher Fellowship Program Lacher Fellowship 100% Salary Support, 07/2018 – 07/2020 Awarded Investigator: Lindsey Roeker I was granted this salary support based on my clinical research portfolio in hematologic malignancy.</p>

**Current Research Support** (duplicate table as needed):

Source	<b>ASH Research Training Award for Fellows</b>
Amount	\$70,000/year
Duration	07/2019 – 12/2020
Principal Investigator	Lindsey Roeker; Mentored by Dr. Anthony Mato
Your Role in Project	Junior Investigator
% Effort	66%

Source	<b>Pfizer Global Medical Grants</b>
Amount	\$358,360
Duration	10/2020 – present
Principal Investigator	Anthony Mato
Your Role in Project	Co-Investigator
% Effort	10%

## I. EXTRAMURAL PROFESSIONAL RESPONSIBILITIES

Activity / Responsibility	Dates
Journal Reviewer: Haematologica, British Journal of Hematology, Leukemia and Lymphoma, Clinical Cancer Research, JCO Global Oncology, Cancers	06/2019 – Present
CancerCare Patient Education Teleconferences, invited speaker	
Life with CLL: Taking Charge of Your Treatment Schedule	11/2018
Treatment of Relapsed/Refractory CLL	06/2019
Update on Chronic Lymphocytic Leukemia (CLL)	04/2020
Coping with the Stresses of Caregiving When Your Loved One Has CLL	05/2020
Lymphoma Research Foundation, invited speaker	
Ask the Doctor, patient education event	12/2018
Regional Lymphoma Workshop, patient education event	05/2019
NY Lymphoma Rounds, provider education event	02/2020
Leukemia Lymphoma Society, invited speaker	
Living Well with CLL, patient education event	05/2019
CLL Society	
Medical advisory board member, invited speaker	07/2019 – Present
2020 Patient Education Forum	09/2020
Curio Science, invited speaker	
Winter national summit on opinions in hematologic malignancies	02/2020
Opinions in CLL workshop moderator	07/2020—10/2020

## J. PROFESSIONAL MEMBERSHIPS

Member/Officer/Fellow/Role	Organization	Dates
Member	American Society of Hematology	07/2017 – Present
Member	American Society of Clinical Oncology	07/2017 – Present
Member	European Hematology Association	03/2019 – 03/2020

## K. HONORS AND AWARDS

Name of award	Date awarded
Georgetown University Phi Beta Kappa	2010
Georgetown University Sigma Xi	2010
American Society of Hematology Abstract Achievement Award	12/2012
Brigham and Women’s Hospital Internal Medicine Residency Resident Mentor Award	05/2017
Memorial Sloan Kettering Cancer Center John Mendelsohn Housestaff Teaching Award	06/2018

## L. BIBLIOGRAPHY

### 1. Articles in professional peer-reviewed journals

1. Vaa BE, Wolanskyj AP, **Roeker L**, Pardananani A, Lasho TL, Finke CM, Tefferi A. Pruritus in primary myelofibrosis: clinical and laboratory correlates. Am J Hematol. 2012 Feb;87(2):136-8. doi: 10.1002/ajh.22215. Epub 2011 Nov 12. PubMed PMID: 22081434.
2. **Roeker LE**, Larson DR, Kyle RA, Kumar S, Dispenzieri A, Rajkumar SV. Risk of acute leukemia and myelodysplastic syndromes in patients with monoclonal gammopathy of undetermined significance (MGUS): a population-based study of 17 315 patients. Leukemia. 2013 Jun;27(6):1391-3. doi:

- 10.1038/leu.2013.34. Epub 2013 Feb 5. PubMed PMID: 23380709; PubMed Central PMCID: PMC3676476.
3. Lim MY, Stephens EK, Novotny P, Price K, Salayi M, **Roeker L**, Peethambaram P, Jatoi A. Self-perceptions of age among 292 chemotherapy-treated cancer patients: Exploring associations with symptoms and survival. *J Geriatr Oncol.* 2013 Jul;4(3):249-54. doi: 10.1016/j.jgo.2013.02.001. PubMed PMID: 23795225; PubMed Central PMCID: PMC3685874.
  4. **Roeker LE**, Gupta V, Gonsalves WI, Wolanskyj AP, Gangat N. Cyclic bicytopenia in a patient with shapiro syndrome. *Case Rep Hematol.* 2013;2013:231713. doi: 10.1155/2013/231713. Epub 2013 Sep 25. PubMed PMID: 24187634; PubMed Central PMCID: PMC3800621.
  5. Handlogten KS\*, Molitor RJ\*, **Roeker LE\***, Narla NP\*, Bachman MJ\*, Quayson S, Owusu-Afriyie O, Adjei E, Ankobea F, Clayton A, Roberts L, MacLaughlin K, Ansong D. Cervical cancer screening in Ghana, west Africa: prevalence of abnormal cytology and challenges for expanding screening. *Int J Gynecol Pathol.* 2014 Mar;33(2):197-202. doi: 10.1097/PGP.0b013e318298a9e6. PubMed PMID: 24487476. (\*co-first authorship)
  6. **Roeker LE**, Wolanskyj AP. Imatinib-associated melanosis of the palate. *Am J Hematol.* 2014 May;89(5):564. doi: 10.1002/ajh.23589. Epub 2014 Mar 3. PubMed PMID: 24030927.
  7. Grogan M, Gertz M, McCurdy A, **Roeker L**, Kyle R, Kushwaha S, Daly R, Dearani J, Rodeheffer R, Frantz R, Lacy M, Hayman S, McGregor C, Edwards B, Dispenzieri A. Long term outcomes of cardiac transplant for immunoglobulin light chain amyloidosis: The Mayo Clinic experience. *World J Transplant.* 2016 Jun 24;6(2):380-8. doi: 10.5500/wjt.v6.i2.380. PubMed PMID: 27358783; PubMed Central PMCID: PMC4919742.
  8. Banerjee D, **Roeker LE**, Grogan M, Swiecicki P, Poterucha J, Heimbach J, Zeldenrust S, Gertz M, Edwards B, Daly R, Klarich KW, Dispenzieri A. Outcomes of Patients With Familial Transthyretin Amyloidosis After Liver Transplantation. *Prog Transplant.* 2017 Sep;27(3):246-250. doi: 10.1177/1526924817715463. Epub 2017 Jul 4. PubMed PMID: 29187090.
  9. Mato AR, Thompson M, Allan JN, Brander DM, Pagel JM, Ujjani CS, Hill BT, Lamanna N, Lansigan F, Jacobs R, Shadman M, Skarbnik AP, Pu JJ, Barr PM, Sehgal AR, Cheson BD, Zent CS, Tuncer HH, Schuster SJ, Pickens PV, Shah NN, Goy A, Winter AM, Garcia C, Kennard K, Isaac K, Dorsey C, Gashonia LM, Singavi AK, **Roeker LE**, Zelenetz A, Williams A, Howlett C, Weissbrot H, Ali N, Khajavian S, Sitlinger A, Tranchito E, Rhodes J, Felsenfeld J, Bailey N, Patel B, Burns TF, Yacur M, Malhotra M, Svoboda J, Furman RR, Nabhan C. Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States. *Haematologica.* 2018 Sep;103(9):1511-1517. doi: 10.3324/haematol.2018.193615. Epub 2018 Jun 7. PubMed PMID: 29880613; PubMed Central PMCID: PMC6119152.
  10. Bange E, Timlin C, Kabel C, Svoboda J, **Roeker L**, Mato AR. Evidence for and Against Green Tea and Turmeric in the Management of Chronic Lymphocytic Leukemia. *Clin Lymphoma Myeloma Leuk.* 2018 Oct;18(10):e421-e426. doi: 10.1016/j.clml.2018.06.021. Epub 2018 Jun 27. Review. PubMed PMID: 30007569.
  11. Mato AR\*, **Roeker LE\***, Allan JN, Pagel JM, Brander DM, Hill BT, Cheson BD, Furman RR, Lamanna N, Tam CS, Handunnetti S, Jacobs R, Lansigan F, Bhavsar E, Barr PM, Shadman M, Skarbnik AP, Goy A, Beach DF, Svoboda J, Pu JJ, Sehgal AR, Zent CS, Tuncer HH, Schuster SJ, Pickens PV, Shah NN, Rhodes J, Ujjani CS, Nabhan C. Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial. *Am J Hematol.* 2018 Nov;93(11):1394-1401. doi: 10.1002/ajh.25261. Epub 2018 Sep 26. PubMed PMID: 30132965. (\*co-first authorship)
  12. Ravi P, Kumar SK, **Roeker L**, Gonsalves W, Buadi F, Lacy MQ, Go RS, Dispenzieri A, Kapoor P, Lust JA, Dingli D, Lin Y, Russell SJ, Leung N, Gertz MA, Kyle RA, Bergsagel PL, Rajkumar SV. Revised diagnostic criteria for plasma cell leukemia: results of a Mayo Clinic study with comparison of outcomes to multiple myeloma. *Blood Cancer J.* 2018 Nov 15;8(12):116. doi: 10.1038/s41408-018-0140-1. PubMed PMID: 30442928; PubMed Central PMCID: PMC6238010.
  13. **Roeker LE**, Kim HT, Glotzbecker B, Nageshwar P, Nikiforow S, Koreth J, Armand P, Cutler C, Alyea EP, Antin JH, Richardson PG, Soiffer RJ, Ho VT. Early Clinical Predictors of Hepatic Venous-Obstructive Disease/Sinusoidal Obstruction Syndrome after Myeloablative Stem Cell Transplantation. *Biol Blood Marrow Transplant.* 2019 Jan;25(1):137-144. doi: 10.1016/j.bbmt.2018.07.039. PubMed PMID: 30081073.

14. Mato AR\*, **Roeker LE\***, Eyre TA, Nabhan C, Lamanna N, Hill BT, Brander DM, Barr PM, Lansigan F, Cheson BD, Singavi AK, Sarraf Yazdy M, Shah NN, Allan JN, Bhavsar EB, Rhodes J, Kennard K, Schuster SJ, Williams AM, Skarbnik AP, Goy AH, Goodfriend JM, Dorsey C, Coombs CC, Tuncer H, Ujjani CS, Jacobs R, Winter AM, Pagel JM, Bailey N, Schuh A, Shadman M, Sitlinger A, Weissbrot H, Muralikrishnan S, Zelenetz A, Kirkwood AA, Fox CP. A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL. *Blood Adv.* 2019 May 28;3(10):1568-1573. doi: 10.1182/bloodadvances.2019000180. PubMed PMID: 31101647; PubMed Central PMCID: PMC6538868. (\*co-first authorship)
15. **Roeker LE**, Fox CP, Eyre TA, Brander DM, Allan JN, Schuster SJ, Nabhan C, Hill BT, Shah NN, Lansigan F, Yazdy M, Cheson BD, Lamanna N, Singavi AK, Coombs CC, Barr PM, Skarbnik AP, Shadman M, Ujjani CS, Tuncer HH, Winter AM, Rhodes J, Dorsey C, Morse H, Kabel C, Pagel JM, Williams AM, Jacobs R, Goy A, Muralikrishnan S, Pearson L, Sitlinger A, Bailey N, Schuh A, Kirkwood AA, Mato AR. Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice. *Clin Cancer Res.* 2019 Jul 15;25(14):4264-4270. doi: 10.1158/1078-0432.CCR-19-0361. Epub 2019 Apr 19. PubMed PMID: 31004001.
16. **Roeker LE**, Sarraf Yazdy M, Rhodes J, Goodfriend J, Narkhede M, Carver J, Mato A. Hypertension in Patients Treated With Ibrutinib for Chronic Lymphocytic Leukemia. *JAMA Netw Open.* 2019 Dec 2;2(12):e1916326. doi: 10.1001/jamanetworkopen.2019.16326. PubMed PMID: 31790561; PubMed Central PMCID: PMC6902749.
17. Eyre TA, Lamanna N, **Roeker LE**, Ujjani CS, Hill BT, Barr PM, Lansigan E, Cheson BD, Yazdy M, Allan JN, Rhodes J, Schuster SJ, Nabhan C, Skarbnik A, Leslie L, Islam P, Whitaker K, Coombs CC, Tuncer HH, Pagel JM, Jacobs R, Winter AM, Bailey N, Sitlinger A, Schuh AH, Follows G, Fox CP, Brander DM, Shadman M, Mato AR. Comparative analysis of targeted novel therapies in relapsed, refractory chronic lymphocytic leukaemia. *Haematologica.* 2020 Feb 20. doi: 10.3324/haematol.2019.241539. [Epub ahead of print]. PubMed PMID: 32079693
18. Eyre TA\*, **Roeker LE\***, Fox CP, Gohill SH, Walewska R, Walter HS, Forconi F, Broom A, Arumainathan A, Brander DM, Allan JN, Schuster SJ, Hill BT, Lansigan F, Cheson BD, Lamanna N, Coombs CC, Barr PM, Skarbnik AP, Shadman M, Ujjani CS, Pearson L, Pagel JM, Jacobs R, Mato AR. The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemia. *Br J Haematol.* 2020 Mar;188(6):918-923. doi: 10.1111/bjh.16271. PubMed PMID: 31682002. (\*co-first authorship)
19. Lewis C, Kim HT, **Roeker LE**, Cutler C, Koreth J, Nikiforow S, Armand P, Gootpu M, Romee R, Glotzbecker B, Nageshwar P, Antin JH, Alyea EP, Richardson P, Soiffer RJ, Ho VT. Incidence, Predictors, and Outcomes of Venous Occlusive Disease/Sinusoidal Obstruction Syndrome after Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation. *Biol Blood Marrow Transplant.* 2020 Mar;26(3):529-539. doi: 10.1016/j.bbmt.2019.10.024. PubMed PMID: 31678537.
20. Mato AR\*, **Roeker LE\***, Jacobs R, Hill BT, Lamanna N, Brander D, Shadman M, Ujjani CS, Sarraf Yazdy M, Perini GF, Pinilla-Ibarz JA, Barrientos J, Skarbnik AP, Torka P, Pu JJ, Pagel JM, Gohil S, Fakhri B, Choi M, Coombs CC, Rhodes J, Barr PM, Portell CA, Parry H, Garcia CA, Whitaker KJ, Winter AM, Sitlinger A, Khajavian S, Grajales-Cruz AF, Isaac KM, Shah P, Akhtar OS, Pocock R, Lam K, Voorhees TJ, Schuster SJ, Rodgers TD, Fox CP, Martinez-Calle N, Munir T, Bhavsar EB, Bailey N, Lee JC, Weissbrot HB, Nabhan C, Goodfriend JM, King AC, Zelenetz AD, Dorsey C, Bigelow K, Cheson BD, Allan JN, Eyre TA. Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK inhibition as an Effective Strategy. *Clin Cancer Res.* 2020 Jul 15;26(14):3589-3596. doi: 10.1158/1078-0432.CCR-19-3815. PubMed PMID: 32198151co-first authorship)
21. Chong EA\*, **Roeker LE\***, Shadman M, Davids MS, Schuster SJ, Mato AR. BTK inhibitors in cancer patients with COVID19: "The winner will be the one who controls that chaos" (Napoleon Bonaparte). *Clin Cancer Res.* 2020 Jul 15;26(14):3514-3516. doi: 10.1158/1078-0432.CCR-20-1427. PubMed PMID: 32345646co-first authorship)
22. Koffman B, Mato A, Byrd JC, Danilov A, Hedrick B, Ujjani C, **Roeker L**, Stephens DM, Davids MS, Pagel JM, Shadman M. Management of CLL patients early in the COVID-19 pandemic: An international survey of CLL experts. *Am J Hematol.* 2020 Aug;95(8):E199-E203. doi: 10.1002/ajh.25851. Epub 2020 May 13. PubMed PMID: 32356356

23. Mato AR\*, **Roeker LE\***, Lamanna N, Allan JN, Leslie L, Pagel JM, Patel K, Osterborg A, Wojenski D, Kamdar M, Huntington SF, Davids MS, Brown JR, Antic D, Jacobs R, Ahn IE, Pu J, Isaac KM, Barr PM, Ujjani CS, Geyer MB, Berman E, Zelenetz AD, Malakhov N, Furman RR, Koropsak M, Bailey N, Hanson L, Perini GF, Ma S, Ryan CE, Wiestner A, Portell CA, Shadman M, Chong EA, Brander DM, Sundaram S, Seddon AN, Seymour E, Patel M, Martinez-Calle N, Munir T, Walewska R, Broom A, Walter H, ElSharkawi D, Parry H, Wilson MR, Patten PEM, Hernández Rivas JA, Miras F, Fernandez-Escalada N, Ghione P, Nabhan C, Lebowitz S, Bhavsar E, Lopez Jimenez J, Naya D, Garcia-Marco JA, Skanland S, Cordoba R, Eyre TA. Outcomes of COVID-19 in Patients with CLL: A Multicenter, International Experience. *Blood*. 2020; 136(10):1134-1143. doi: 10.1182/blood.2020006965. PubMed PMID: 32688395co-first authorship)
24. **Roeker LE**, Dreger P, Brown JR, Lahoud OB, Eyre TA, Brander DM, Skarbnik A, Coombs CC, Kim HT, Davids M, Manchini ST, Voorhees TJ, Orchard KH, Walter HS, Arumainathan AK, Sitlinger A, Park JH, Geyer MB, Zelenetz AD, Sauter CS, Giralt SA, Perales MA, Mato AR. Allogeneic stem cell transplantation for chronic lymphocytic leukemia (CLL) in the era of novel agents. *Blood Adv*. 2020 Aug 25;4(16):3977-3989. doi: 10.1182/bloodadvances.2020001956. PubMed PMID: 32841336.
25. **Roeker LE**, Knorr DA, Pessin MS, Ramanathan LV, Thompson MC, Leslie LA, Zelenetz AD, Mato AR. Anti-SARS-CoV-2 antibody response in patients with chronic lymphocytic leukemia. *Leukemia*. 2020 Aug 27:1-3. doi: 10.1038/s41375-020-01030-2. [Epub ahead of print]. PubMed PMID: 32855439
26. Ujjani C, Mato A, Hill BT, Allan JN, Lansigan F, Jacobs R, Skarbnik A, Tuncer H, Pagel J, Brander D, Cheson B, Barr P, **Roeker LE**, Pu J, Shah NN, Goy A, Schuster SJ, Lamanna N, Sehgal A, Tam CS, Shadman M. The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy. *Blood Lymphat Cancer*. 2020 Aug 24;10:1-5. doi: 10.2147/BLCTT.S262592. eCollection 2020. PMID: 32943973
27. Cuneo A, Mato AR, Rigolin GM, Piciocchi A, Gentile M, Laurenti L, Allan JN, Pagel JM, Brander DM, Hill BT, Winter A, Lamanna N, Tam CS, Jacobs R, Lansigan F, Barr PM, Shadman M, Skarbnik AP, Pu JJ, Sehgal AR, Schuster SJ, Shah NN, Ujjani CS, **Roeker L**, Orlandi EM, Billio A, Trentin L, Spacek M, Marchetti M, Tedeschi A, Ilariucci F, Gaidano G, Doubek M, Farina L, Molica S, Di Raimondo F, Coscia M, Mauro FR, de la Serna J, Medina Perez A, Ferrarini I, Cimino G, Cavallari M, Cucci R, Vignetti M, Foà R, Ghia P; GIMEMA, European Research Initiative (ERIC) on CLL, US study group. Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study. *Cancer Med*. 2020 Sep 24. doi: 10.1002/cam4.3470. [Epub ahead of print] PMID: 32969597

## 2. Reviews

## 3. Books

## 4. Chapters

1. Roeker LE, Ho VT. Venous-occlusive disease/sinusoidal obstructive syndrome (VOD/SOS). In: Alyea EP, Ho VT, Glotzbecker BE, Nageshwar P, ed. *Handbook of Stem Cell Transplantation and Cellular Therapy Management*. Springer Publishing Company; 2020

## 5. Other (media, DVD's, etc.)

1. **Roeker L**. Vital signs are vital: Pain. *ACP Hospitalist* 2014 Jul.
2. **Roeker LE**, Bachman M, Narla N, Molitor R, Handlogten K, MacLaughlin K. Planning an international research project. *Student BMJ* 2014 Apr;22: 24-5.
3. "Master class CLL: Achieving durable response after progression on ibrutinib." Projects in Knowledge, Inc. CME activity.
4. "Optimal sequencing of therapy for relapsed CLL: A case study." PrimeOncology CME activity.

## 6. Abstracts:

1. **Roeker LE**, Larson D, Kyle RA, Kumar S, Dispenzieri A, Rajkumar SV. Development of myelodysplastic syndrome and acute leukemias in patients with monoclonal gammopathy of undetermined significance (MGUS): A population-based study of 17,315 patients. *Blood* 2012;120:21.
2. **Roeker LE**, Wolanskyj A, Elliott M, Hogan W, Litzow M, Al-Kali A. Treatment-related AML patients previously treated with taxanes for breast cancer have similar outcomes as de novo AML. *Blood* 2012;120:3555. (ASH Abstract Achievement Award Winner)
3. **Roeker LE**, Larson D, Kyle R, Kumar SK, Dispenzieri A, Rajkumar V. Development of solid malignancies in patients with monoclonal gammopathy of undetermined significance (MGUS): A population-based study of 17,315 patients. *Blood* 2013;122:3134.
4. **Roeker LE**, Horkan CM, Gibbons FK, Christopher KB. Eosinopenia in ICU survivors and post-hospital outcomes. *Intensive Care Med Exp* 2016;4(Suppl 1):30.
5. **Roeker LE**, Kim HT, Ho VT, Richardson PG, Soiffer RJ. Early clinical predictors of hepatic veno-occlusive disease after myeloablative hematopoietic stem cell transplantation: A single-center report of 205 cases. *Biol Blood Marrow Transplant* 2017;23(3):S94.
6. **Roeker LE**, Fox CP, Eyre TA, Allan JN, Schuster SJ, Nabhan C, Hill BT, Shah NN, Lansigan F, Yazdy M, Lamanna N, Cheson B, Singavi AK, Coombs CC, Barr P, Skarbnik AP, Shadman M, Tuncer HH, Ujjani CS, Winter AM, Rhodes J, Dorsey C, Morse H, Pagel JM, Williams AM, Jacobs R, Goy A, Muralikrishnan S, Pearson L, Sitlinger A, Bailey N, Schuh A, Brander DM, Kirkwood AA, Mato AR. Adverse events, patterns of tumor lysis syndrome prophylaxis and management, and dosing patterns in a large cohort of venetoclax treated CLL patients in community and academic settings. *Blood* 2018;132:4410.
7. Mato AR, **Roeker LE**, Eyre TA, Nabhan C, Lamanna N, Hill BT, Brander DM, Barr P, Lansigan F, Cheson G, Singavi AK, Yazdy M, Shah NN, Allan JN, Bhavsar EB, Rhodes J, Kennard K, Schuster SJ, Williams AM, Skarbnik AP, Goy A, Coombs CC, Tuncer HH, Ujjani CS, Jacobs R, Winter AM, Pagel JM, Bailey N, Schuh A, Shadman M, Sitlinger A, Weissbrot H, Muralikrishnan S, Kirkwood AA, Fox CP. Venetoclax as monotherapy or in combination: Patterns of use and predictors of outcomes in an international multicenter study of CLL patients. *Blood* 2018;132:3142.
8. Mato AR, Svoboda J, Luning Prak ET, Schuster SJ, Tsao P, Dorsey C, Becker PS, Brander DM, Nasta SD, Landsburg DJ, King CM, Morigan B, Kennard K, **Roeker LE**, Zelenetz AD, Purdom M, Paskalis D, Sportelli P, Miskin HP, Weiss MS, Shadman M. Phase I/II study of umbralisib (TGR-1202) in combination with ublituximab (TG-1101) and pembrolizumab in patients with relapsed/refractory CLL and Richter's transformation. *Blood* 2018;132:297.
9. **Roeker LE**, Yazdy M, Gashonia L, Goodfriend J, Narkhede M, Rhodes J, Kennard K, Morse H, Dorsey C, Battiato K, Peterson M, Carver J, Schuster S, Cheson B, Mato AR. Hypertension in patients treated with ibrutinib for chronic lymphocytic leukemia (CLL). Poster session presented at: 24<sup>th</sup> Congress of European Hematology Association; 2019 Jun 13-16; Amsterdam, Netherlands.
10. **Roeker L**, Brander D, Coombs C, Schuster S, Allan J, Hill B, Lansigan E, Cheson BD, Yazdy M, Lamanna N, Barr P, Skarbnik A, Ujjani C, Shadman M, Rhodes J, Pagel JM, Jacobs R, Goy A, Shah N, Zelenetz A, Schuh A, Eyre T, Fox C, Mato A. Predicting tumor lysis syndrome in venetoclax-treated CLL patients. Poster and oral presentation presented at: XVIII iwCLL International Workshop on CLL; 2019 Sep 20-23; Edinburgh, Scotland.
11. Ujjani C, Mato A, Hill B, Allan J, Lansigan E, Skarbnik A, Jacobs R, Thompson M, Svoboda J, Tuncer HH, Pagel J, Brander D, Cheson BD, Barr P, Zent CS, Rhodes J, **Roeker L**, Pu J, Handunnetti S, Nabhan C, Shah N, Goy A, Pickens P, Schuster S, Lamanna N, Sehgal A, Tam C, Shadman M. The impact of age on survival in CLL patients receiving ibrutinib as initial therapy. Poster session presented at: XVIII iwCLL International Workshop on CLL; 2019 Sep 20-23; Edinburgh, Scotland.
12. Brander D, Eyre T, Nabhan C, Lamanna N, Hill B, Barr P, Lansigan E, Cheson BD, **Roeker L**, Yazdy M, Shah N, Allan J, Rhodes J, Kennard K, Schuster S, Skarbnik A, Goy A, Dorsey C, Coombs C, Tuncer HH, Ujjani C, Winter A, Pagel J, Bailey N, Schuh A, Shadman M, Sitlinger A, Weissbrot H, Kirwood A, Fox C, Jacobs R, Mato A. Chronic lymphocytic leukemia (CLL)-IPI score and outcomes for venetoclax treated CLL patients in a large multicenter cohort. Poster session presented at: XVIII iwCLL International Workshop on CLL; 2019 Sep 20-23; Edinburgh, Scotland.

13. Sarraf Yazdy M, Mato AR, **Roeker LE**, Jarral U, Ujjani CS, Shadman M, Skarbnik A, Whitaker KJ, Deonaraine I, Kabel CC, Stump SE, Goodfriend J, Pagel JM, Bailey N, Patel K, Jacobs R, Feldman TA, Leslie LA, Goy A, Coombs CC, Muluneh B, Khajavian S, Lamanna N, Weissbrot H, Weiss J, Cheson BD. Toxicities and outcomes of acalabrutinib-treated patients with chronic lymphocytic leukemia: A retrospective analysis of real world patients. *Blood* 2019;134(Supplement\_1):4311.
14. Shadman M, Sail K, Manzoor BS, Sarraf Yazdy M, Hill BT, Tuncer HH, Allan HN, Ujjani CS, Emechebe N, Kamalakar R, Sharmokh S, Dingfeng Jiang D, Pena G, Marshall T, Nielsen J, Barr PM, Brown JR, Schuh A, Eyre TA, Lamanna N, Wierda WG, Skarbnik A, **Roeker LE**, Bannerji R, Pauff JM, Schuster SJ, Follows GA, Cheson BD, Eichhorst BF, Brander DM, Pivneva I, Guerin A, Mato AR. Treatment discontinuation patterns for patients with CLL in the real-world settings: Results from a multi-center study. *Blood* 2019;134(Supplement\_1):3048.
15. **Roeker LE**, Brown JR, Drege P, Lahoud OB, Eyre TA, Brander DM, Skarbnik A, Coombs CC, Kim HT, Manchini ST, Voorhees TJ, Orchard KH, Walter HS, Arumainathan AK, Sitlinger A, Sauter CS, Giralt SA, Perales MA, Mato AR. Allogeneic stem cell transplantation (alloHSCT) for chronic lymphocytic leukemia (CLL) in the era of novel agents. *Blood* 2019;134(Supplement\_1):3321.
16. Mato AR, Sail K, Sarraf Yazdy M, Hill BT, Shadman M, Manzoor BS, Tuncer HH, Allan JN, Ujjani CS, Sharmokh S, Jiang DD, Pena G, Marshall T, Nielsen J, Barr PM, Brown JR, Schuh A, Eyre TA, Wierda WG, Skarbnik A, **Roeker LE**, Bannerji R, Pauff JM, Schuster SJ, Follows GA, Cheson BD, Eichhorst BF, Brander DM, Pivneva I, Lamanna N. Treatment sequences and outcomes of patients with CLL treated with venetoclax and other novel agents post introduction of novel therapies. *Blood* 2019;134(Supplement\_1):1756.
17. Mato AR, **Roeker LE**, Eyre TA, Jacobs R, Hill BT, Lamanna N, Brander DM, Shadman M, Ujjani C, Yazdy M, Perini GF, Pinilla Ibarz J, Barrientos JC, Skarbnik A, Torka P, Pu JJ, Pagel JM, Gohil S, Fakhri B, Choi MY, Coombs CC, Rhodes J, Barr PM, Portell CA, Parry H, Garcia CA, Whitaker KJ, Winter AM, Sitlinger A, Khajavian S, Grajales-Cruz AF, Isaac K, Shah P, Akhtar OS, Pocock R, Lam K, Voorhees TJ, Schuster SJ, Rodgers TD, Martinez-Calle N, Munir T, Bhavsar EB, Bailey N, Lee JC, Weissbrot H, Nabhan C, Goodfriend J, King AC, Zelenetz AD, Dorsey C, Bigelow K, Cheson BD, Fox CP, Allan JN. Efficacy of therapies following venetoclax discontinuation in CLL: Focus on B-cell receptor signal transduction inhibitors and cellular therapies. *Blood* 2019;134(Supplement\_1):502.
18. Mato AR, Schuster SJ, Foss FM, Isufi I, Ding W, Brander DM, Sitlinger A, Tun HW, Alhaj Moustafa M, Kennard K, King CM, Koehler A, Aitken C, He W, Kearney A, Gui M, Anderson BD, Rosenthal AC, **Roeker LE**, Huntington SF. A phase Ia/Ib study exploring the synthetic lethality of the orally administered novel BTK inhibitor, Dtrmwxs-12 (DTRM-12), in combination with everolimus and pomalidomide in patients with relapsed/refractory CLL, DLBCL or other B-cell lymphomas. *Blood* 2019;134(Supplement\_1):810.
19. Ujjani CS, **Roeker LE**, Shadman M, Whitaker KJ, Jacob AP, Geyer MB, Dorsey C, Zelenetz AD, Mato AR. Veneto-STOP study: sequential assessment of minimal residual disease by next generation sequencing to optimize outcomes and minimize exposure in venetoclax-treated CLL patients. *Blood* 2019;134(Supplement\_1):1758.
20. Bantilan KS, Soumerai JD, **Roeker LE**, Mato AR, Zelenetz AD. Time to second treatment as a proxy for overall survival in CLL/SLL: Identifying risk factors to help guide treatment selection. *Blood* 2019;134(Supplement\_1):4299.

7. Presentations: Optional, **other than invited**. List 10-20 best or most recent only.

1. Risk of acute leukemia and myelodysplastic syndrome in monoclonal gammopathy of undetermined significance: a population-based study of 17,315 patients. American Society of Hematology Annual Meeting, 2012 Dec, Atlanta, GA.
2. Planning a medical student directed international research project. AAFP Global Health Workshop, 2013 Oct, Baltimore, MD.
3. Eosinopenia in ICU survivors and post-hospital outcomes. LIVES 2016: Annual Congress of the European Society of Intensive Care Medicine, 2016 Oct, Milan, Italy.

4. Early clinical predictors of hepatic veno-occlusive disease after myeloablative hematopoietic stem cell transplantation: a single-center report of 205 cases. BMT Tandem Meetings, 2017 Feb, Orlando, FL.